Chu Charles C, Catera Rosa, Hatzi Katerina, Yan Xiao-Jie, Zhang Lu, Wang Xiao Bo, Fales Henry M, Allen Steven L, Kolitz Jonathan E, Rai Kanti R, Chiorazzi Nicholas
The Feinstein Institute for Medical Research, North Shore-Long Island Jewish (LIJ) Health System, Manhasset, NY, USA.
Blood. 2008 Dec 15;112(13):5122-9. doi: 10.1182/blood-2008-06-162024. Epub 2008 Sep 23.
Leukemic B lymphocytes of a large group of unrelated chronic lymphocytic leukemia (CLL) patients express an unmutated heavy chain immunoglobulin variable (V) region encoded by IGHV1-69, IGHD3-16, and IGHJ3 with nearly identical heavy and light chain complementarity-determining region 3 sequences. The likelihood that these patients developed CLL clones with identical antibody V regions randomly is highly improbable and suggests selection by a common antigen. Monoclonal antibodies (mAbs) from this stereotypic subset strongly bind cytoplasmic structures in HEp-2 cells. Therefore, HEp-2 cell extracts were immunoprecipitated with recombinant stereotypic subset-specific CLL mAbs, revealing a major protein band at approximately 225 kDa that was identified by mass spectrometry as nonmuscle myosin heavy chain IIA (MYHIIA). Reactivity of the stereotypic mAbs with MYHIIA was confirmed by Western blot and immunofluorescence colocalization with anti-MYHIIA antibody. Treatments that alter MYHIIA amounts and cytoplasmic localization resulted in a corresponding change in binding to these mAbs. The appearance of MYHIIA on the surface of cells undergoing stress or apoptosis suggests that CLL mAb may generally bind molecules exposed as a consequence of these events. Binding of CLL mAb to MYHIIA could promote the development, survival, and expansion of these leukemic cells.
一大群无亲缘关系的慢性淋巴细胞白血病(CLL)患者的白血病B淋巴细胞表达由IGHV1-69、IGHD3-16和IGHJ3编码的未突变重链免疫球蛋白可变(V)区,其重链和轻链互补决定区3序列几乎相同。这些患者随机产生具有相同抗体V区的CLL克隆的可能性极低,这表明存在共同抗原的选择作用。来自这个定型亚群的单克隆抗体(mAb)能强烈结合HEp-2细胞中的细胞质结构。因此,用重组的定型亚群特异性CLL mAb对HEp-2细胞提取物进行免疫沉淀,结果显示一条约225 kDa的主要蛋白带,经质谱鉴定为非肌肉肌球蛋白重链IIA(MYHIIA)。通过蛋白质印迹法以及与抗MYHIIA抗体的免疫荧光共定位,证实了定型mAb与MYHIIA的反应性。改变MYHIIA数量和细胞质定位的处理导致与这些mAb的结合发生相应变化。在经历应激或凋亡的细胞表面出现MYHIIA,这表明CLL mAb可能通常结合因这些事件而暴露的分子。CLL mAb与MYHIIA的结合可能促进这些白血病细胞的发育、存活和增殖。